1.56
price down icon6.59%   -0.11
after-market Handel nachbörslich: 1.50 -0.06 -3.85%
loading
Schlusskurs vom Vortag:
$1.67
Offen:
$1.61
24-Stunden-Volumen:
139.63K
Relative Volume:
0.14
Marktkapitalisierung:
$72.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-82.60M
KGV:
-0.7573
EPS:
-2.06
Netto-Cashflow:
$-48.61M
1W Leistung:
-18.32%
1M Leistung:
-30.97%
6M Leistung:
-54.65%
1J Leistung:
-52.15%
1-Tages-Spanne:
Value
$1.515
$1.6274
1-Wochen-Bereich:
Value
$1.515
$1.87
52-Wochen-Spanne:
Value
$1.49
$6.06

Vigil Neuroscience Inc Stock (VIGL) Company Profile

Name
Firmenname
Vigil Neuroscience Inc
Name
Telefon
857-254-4445
Name
Adresse
100 FORGE ROAD, WATERTOWN
Name
Mitarbeiter
69
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
VIGL's Discussions on Twitter

Vergleichen Sie VIGL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VIGL
Vigil Neuroscience Inc
1.56 72.81M 0 -82.60M -48.61M -2.06
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-04 Eingeleitet William Blair Outperform
2023-12-19 Herabstufung Morgan Stanley Equal-Weight → Underweight
2023-10-18 Eingeleitet JMP Securities Mkt Outperform
2023-03-31 Eingeleitet Mizuho Buy
2022-09-16 Eingeleitet Wedbush Outperform
2022-08-29 Eingeleitet H.C. Wainwright Buy
2022-02-01 Eingeleitet Guggenheim Buy
2022-02-01 Eingeleitet Jefferies Buy
2022-02-01 Eingeleitet Morgan Stanley Equal-Weight
2022-02-01 Eingeleitet Stifel Buy
Alle ansehen

Vigil Neuroscience Inc Aktie (VIGL) Neueste Nachrichten

pulisher
Apr 02, 2025

Vigil Neuroscience Presents Data on its Small Molecule - GlobeNewswire

Apr 02, 2025
pulisher
Apr 02, 2025

Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials - Investing.com India

Apr 02, 2025
pulisher
Apr 02, 2025

Vigil presents data on oral small molecule program including VG-3927 - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Clinical Data Breakthrough: Vigil's New Alzheimer's Drug Targets Both Aβ and Tau Pathologies - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Vigil Neuroscience Reports 2024 Results and Clinical Progress - TipRanks

Apr 02, 2025
pulisher
Mar 31, 2025

Vigil Neuroscience Files Secondary Stock Shelf - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Large Decline in Short Interest - Defense World

Mar 31, 2025
pulisher
Mar 18, 2025

Vigil Neuroscience (VIGL) to Release Earnings on Tuesday - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

H.C. Wainwright cuts Vigil Neuroscience stock target to $14 By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

H.C. Wainwright cuts Vigil Neuroscience stock target to $14 - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

FY2029 Earnings Forecast for VIGL Issued By Wedbush - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Q1 Earnings Estimate for VIGL Issued By William Blair - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

HC Wainwright Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World

Mar 16, 2025
pulisher
Mar 16, 2025

Wedbush Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World

Mar 16, 2025
pulisher
Mar 14, 2025

Vigil Neuroscience Inc.: Promising Biomarker Data and Strategic Advancements Justify Buy Rating - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Wedbush Cuts Price Target on Vigil Neuroscience to $13 From $24, Keeps Outperform Rating - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Stifel maintains Buy on Vigil Neuroscience, target at $11 By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Vigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share Dilution - TipRanks

Mar 14, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Stifel maintains Buy on Vigil Neuroscience, target at $11 - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience, Inc. SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience, Inc. Reports Positive Phase 1 Data for VG-3927 and Outlines Upcoming Milestones in Alzheimer’s Disease and ALSP Treatment Programs - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience, Inc. Loss At -$23.83 Mln In Q4 - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience Reports Fourth Quarter and Full Year - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil's Alzheimer's Drug Shows 50% Brain Biomarker Reduction in Phase 1 Success - StockTitan

Mar 13, 2025
pulisher
Mar 13, 2025

SPY ETF News, 3/13/2025 - The Globe and Mail

Mar 13, 2025
pulisher
Mar 11, 2025

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Vigil Neuroscience To Present At The Stifel 2025 Virtual CNS Forum - MENAFN.COM

Mar 11, 2025
pulisher
Mar 11, 2025

Exclusive CNS Forum: Vigil Neuroscience Reveals Latest Breakthroughs in Neurodegeneration Treatment - StockTitan

Mar 11, 2025
pulisher
Mar 06, 2025

Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely? - Yahoo Finance

Mar 06, 2025
pulisher
Mar 05, 2025

Best Stock to Buy Right Now: Dutch Bros vs. Starbucks - The Globe and Mail

Mar 05, 2025
pulisher
Mar 04, 2025

Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Drops By 43.6% - Defense World

Mar 04, 2025
pulisher
Mar 01, 2025

Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 01, 2025
pulisher
Feb 20, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - PR Newswire

Feb 20, 2025
pulisher
Feb 17, 2025

What Did We Find About Insider Trading At Vigil Neuroscience Inc (NASDAQ: VIGL)? - Stocks Register

Feb 17, 2025
pulisher
Feb 16, 2025

Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial - MSN

Feb 16, 2025
pulisher
Feb 16, 2025

Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 145.8% - MarketBeat

Feb 16, 2025
pulisher
Feb 14, 2025

abrdn plc Purchases 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat

Feb 14, 2025
pulisher
Feb 09, 2025

VIGLVigil Neuroscience, Inc. Latest Stock News & Market Updates - StockTitan

Feb 09, 2025
pulisher
Feb 06, 2025

VIGL Stock Update: Vigil Neuroscience Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle

Feb 06, 2025
pulisher
Feb 05, 2025

The Attractiveness of Investing In Vigil Neuroscience Inc (VIGL) is Growing - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Are Vigil Neuroscience Inc’shares a good deal? - US Post News

Feb 05, 2025
pulisher
Jan 30, 2025

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire

Jan 30, 2025
pulisher
Jan 30, 2025

Neurodegenerative Disease Pioneer Vigil to Reveal Latest Developments at Major Biotech Conference - StockTitan

Jan 30, 2025

Finanzdaten der Vigil Neuroscience Inc-Aktie (VIGL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):